Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance

J Cell Mol Med. 2020 Mar;24(5):2942-2955. doi: 10.1111/jcmm.14910. Epub 2020 Jan 19.

Abstract

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative stem cell disorder characterized by the constitutively active BCR-ABL tyrosine kinase. The LIM and SH3 domain protein 1 (LASP1) has recently been identified as a novel BCR-ABL substrate and is associated with proliferation, migration, tumorigenesis and chemoresistance in several cancers. Furthermore, LASP1 was shown to bind to the chemokine receptor 4 (CXCR4), thought to be involved in mechanisms of relapse. In order to identify potential LASP1-mediated pathways and related factors that may help to further eradicate minimal residual disease (MRD), the effect of LASP1 on processes involved in progression and maintenance of CML was investigated. The present data indicate that not only overexpression of CXCR4, but also knockout of LASP1 contributes to proliferation, reduced apoptosis and migration as well as increased adhesive potential of K562 CML cells. Furthermore, LASP1 depletion in K562 CML cells leads to decreased cytokine release and reduced NK cell-mediated cytotoxicity towards CML cells. Taken together, these results indicate that in CML, reduced levels of LASP1 alone and in combination with high CXCR4 expression may contribute to TKI resistance.

Keywords: BCR-ABL; CML; CXCR4; LASP1; nilotinib; precursor cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism*
  • Adenosine Triphosphate / metabolism
  • Cell Adhesion / drug effects
  • Cell Death / drug effects
  • Cell Degranulation / drug effects
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cytoskeletal Proteins / metabolism*
  • Drug Resistance, Neoplasm* / drug effects
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Knockout Techniques*
  • Humans
  • Imatinib Mesylate / pharmacology
  • Imatinib Mesylate / therapeutic use
  • K562 Cells
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / metabolism
  • Killer Cells, Natural / physiology
  • LIM Domain Proteins / metabolism*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Protein Biosynthesis / drug effects
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Receptors, CXCR4 / metabolism*
  • Transcription, Genetic / drug effects
  • Treatment Outcome

Substances

  • Adaptor Proteins, Signal Transducing
  • CXCR4 protein, human
  • Cytoskeletal Proteins
  • LASP1 protein, human
  • LIM Domain Proteins
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptors, CXCR4
  • Imatinib Mesylate
  • Adenosine Triphosphate
  • nilotinib